New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background and Aims: Some oncogenes encode transcription factors, but few drugs have been successfully developed to block their activity specifically in cancer cells. The transcription factor SALL4 is aberrantly expressed in solid tumor and leukemia cells. We developed a screen to identify compounds that reduce the viability of liver cancer cells that express high levels of SALL4 and we investigated their mechanisms. Methods: We developed a stringent high-throughput screening platform comprising unmodified SNU-387 and SNU-398 liver cancer cell lines and SNU-387 cell lines engineered to express low and high levels of SALL4. We screened 1597 pharmacologically active small molecules and 21,575 natural product extracts from plant, bacteria, and fungal sources for those that selectively reduce the viability of cells with high levels of SALL4 (SALL4hi cells). We compared gene expression patterns of SALL4hi cells vs SALL4-knockdown cells using RNA-seq and real-time PCR analyses. Xenograft tumors were grown in NOD/SCID gamma mice from SALL4hi SNU-398 or HCC26.1 cells or from SALL4lo PDX cells; mice were given injections of identified compounds or sorafenib and the effects on tumor growth were measured. Results: Our screen identified 1 small molecule (PI-103) and 4 natural compound analogues (oligomycin, efrapeptin, antimycin, and leucinostatin) that selectively reduced viability of SALL4hi cells. We performed validation studies, and 4 of these compounds were found to inhibit oxidative phosphorylation. The ATP synthase inhibitor oligomycin reduced the viability of SALL4hi hepatocellular carcinoma and non-small–cell lung cancer cell lines with minimal effects on SALL4lo cells. Oligomycin also reduced the growth of xenograft tumors grown from SALL4hi SNU-398 or HCC26.1 cells, to a greater extent than sorafenib, but oligomycin had little effect on tumors grown from SALL4lo PDX cells. Oligomycin was not toxic to mice. Analyses of chromatin immunoprecipitation sequencing data revealed that SALL4 binds approximately 50% of mitochondrial genes, including many oxidative phosphorylation genes, to activate their transcription. In comparing SALL4hi and SALL4-knockdown cells, we found SALL4 to increase oxidative phosphorylation, oxygen consumption rate, mitochondrial membrane potential, and utilization of oxidative phosphorylation-related metabolites to generate ATP. Conclusions: In a screen for compounds that reduce the viability of cells that express high levels of the transcription factor SALL4, we identified inhibitors of oxidative phosphorylation, which slowed the growth of xenograft tumors from SALL4hi cells in mice. SALL4 activates transcription of genes that regulate oxidative phosphorylation to increase oxygen consumption, mitochondrial membrane potential, and ATP generation in cancer cells. Inhibitors of oxidative phosphorylation might be used for treatment of liver tumors with high levels of SALL4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Combinatorial patterns of histone acetylations and methylations in the human genome
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Peng, W., Zhang, M. Q., et al. (2008) · Nature Genetics · doi:10.1038/ng.154 · Cited by 2,331
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661
Zhang, J., Tam, W.-L., Tong, G. Q., Wu, Q., Chan, H.-Y., Soh, B.-S., Lou, Y., Yang, J., Ma, Y., Chai, L., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1481 · Cited by 568
Self-citationCancer Cell Lines for Drug Discovery and Development
Wilding, J. L., & Bodmer, W. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2971 · Cited by 432
Nutrient acquisition strategies of mammalian cells
Palm, W., & Thompson, C. B. (2017) · Nature · doi:10.1038/nature22379 · Cited by 388
Oncofetal Gene SALL4 in Aggressive Hepatocellular Carcinoma
Yong, K. J., Gao, C., Lim, J. S. J., Yan, B., Yang, H., Dimitrov, T., Kawasaki, A., Ong, C. W., Wong, K.-F., Lee, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300297 · Cited by 257
Self-citationLim, C. Y., Tam, W.-L., Zhang, J., Ang, H. S., Jia, H., Lipovich, L., Ng, H.-H., Wei, C.-L., Sung, W. K., Robson, P., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.004 · Cited by 224
Self-citation
Cited by
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K.-W., Guan, X.-Y., & Ma, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 460
Self-citationSALL4: An Intriguing Therapeutic Target in Cancer Treatment
Moein, S., Tenen, D. G., Amabile, G., & Chai, L. (2022) · Cells · doi:10.3390/cells11162601 · Cited by 35
Self-citationDeveloping Liver Microphysiological Systems for Biomedical Applications
Wang, J., Wu, X., Zhao, J., Ren, H., & Zhao, Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302217 · Cited by 27
SALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms
Wang, T., Jin, Y., Wang, M., Chen, B., Sun, J., Zhang, J., Yang, H., Deng, X., Cao, X., Wang, L., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00812-z · Cited by 9
Targeting transcription factors through an IMiD independent zinc finger domain
Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00241-3 · Cited by 8
“Isogenic cell lines speci fi cally expressing SALL4A (SNU387-TgSALL4A) or SALL4B (SNU387-TgSALL4B) were tested alongside SNU398 and SNU387 cells.”
InfluentialSelf-citation
Metadata
- Authors
- Tan, J. L., Li, F., Yeo, J. Z., Yong, K. J., Bassal, M. A., Ng, G. H., Lee, M. Y., Leong, C. Y., Tan, H. K., Wu, C.-S., Liu, B. H., Chan, T. H., Tan, Z. H., Chan, Y. S., Wang, S., Lim, Z. H., Toh, T. B., Hooi, L., Low, K. N., Ma, S., Kong, N. R., Stein, A. J., Wu, Y., Thangavelu, M. T., Suzuki, A., Periyasamy, G., Asara, J. M., Dan, Y. Y., Bonney, G. K., Chow, E. K., Lu, G.-D., Ng, H. H., Kanagasundaram, Y., Ng, S. B., Tam, W. L., Tenen, D. G., & Chai, L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 157
- Issue
- 6
- Pages
- 1615-1629.e17
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2969431868
- Cited by
- 64
- References
- 20
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. https://app.cochat.ai/papers/10.1053/j.gastro.2019.08.022
- The paper
- Tan, J. L., Li, F., Yeo, J. Z., Yong, K. J., Bassal, M. A., Ng, G. H., Lee, M. Y., Leong, C. Y., Tan, H. K., Wu, C.-S., Liu, B. H., Chan, T. H., Tan, Z. H., Chan, Y. S., Wang, S., Lim, Z. H., Toh, T. B., Hooi, L., Low, K. N., . . . Chai, L. (2019). New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.08.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.